An early-stage medical technology company structured around development of wireless, catheter-free, urodynamic monitoring, Bright URO Inc - having been already in receipt of a straight-to-Phase II NIH award in 2021 - in the Summer 2022 it was announced that that Phase II had increased to $2M. The firm is structured around building the next generation of diagnostic devices for Urology utilizing advanced hardware, software, and data science capable of unlocking new data streams and offering actionable insight for clinicians: a medical device company with a mission to transform care for lower urinary tract symptoms (LUTS) through innovations in urodynamics,
